Cayman Chemical Receives CEP for Latanoprost API from EDQM
Cayman Chemical, a world leader in the manufacture of prostaglandins for both research use and as active pharmaceutical ingredients (APIs), has been granted a CEP for its latanoprost API. Cayman Chemical is the first company in the USA to receive a CEP for latanoprost. ANN ARBOR, Mich.,... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 19, 2023 Category: Pharmaceuticals Source Type: news

NIH rejects another attempt to'march-in' on Astellas' prostate cancer drug over excessive price
The Na­tion­al In­sti­tutes of Health has again de­clined to use so-called “march-in” rights to low­er the price of Astel­las and Pfiz­er’s prostate can­cer drug Xtan­di de­spite be­ing in­vent­ed at UCLA with grants from the US Army and NIH. “Giv­en the re­main­ing patent life and the lengthy…#ucla #usarmy #nih #robertsachs #clarelove #bayhdoleact #jamielove #xalatan #bidenadministrations #hhs (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2023 Category: Consumer Health News Source Type: news

FDA Approves Iyuzeh (latanoprost ophthalmic solution) for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension
Iyuzeh™ (latanoprost ophthalmic solution) 0.005% is the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA) in the United States LEXINGTON, Massachusetts– December... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2022 Category: Drugs & Pharmacology Source Type: news

Medical Researcher and Philanthropist Laszlo Bito Dies at 87
His work contributed to the development of the drug Xalatan, a treatment for glaucoma. (Source: The Scientist)
Source: The Scientist - December 2, 2021 Category: Science Tags: News & Opinion Source Type: news

Omidenepag Matches Latanoprost for Glaucoma Omidenepag Matches Latanoprost for Glaucoma
A phase 3 noninferiority trial shows omidenepag almost as efficacious, but with more side effects than latanoprost in people with glaucoma or intraocular hypertension.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Xelpros (latanoprost) Ophthalmic
Title: Xelpros (latanoprost) OphthalmicCategory: MedicationsCreated: 3/17/2021 12:00:00 AMLast Editorial Review: 3/17/2021 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - March 17, 2021 Category: Opthalmology Source Type: news

Xelpros (Latanoprost Ophthalmic Emulsion) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 4, 2021 Category: Drugs & Pharmacology Source Type: news

EMA Panel Backs Roclanda Eyedrops, New Option for Glaucoma EMA Panel Backs Roclanda Eyedrops, New Option for Glaucoma
The fixed-dose combination of latanoprost and netarsudil is for adults with primary open-angle glaucoma or ocular hypertension for whom monotherapy fails.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 16, 2020 Category: Drugs & Pharmacology Tags: Ophthalmology News Source Type: news

Rocklatan (Netarsudil and Latanoprost Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 11, 2020 Category: Drugs & Pharmacology Source Type: news

New Fixed-Dose, Once-Daily Combo Eyedrop Shows Efficacy in Glaucoma New Fixed-Dose, Once-Daily Combo Eyedrop Shows Efficacy in Glaucoma
There is a sound rationale why combining netarsudil and latanoprost would work so well.Medscape Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 10, 2019 Category: Opthalmology Tags: Ophthalmology Viewpoint Source Type: news

Latanoprost Ophthalmic Solution 0.005% (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - April 10, 2019 Category: Drugs & Pharmacology Source Type: news

Rocklatan (Netarsudil and Latanoprost Ophthalmic Solution) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 22, 2019 Category: Drugs & Pharmacology Source Type: news

Aerie wins FDA nod for second glaucoma drug
Aerie Pharmaceuticals (NSDQ:AERI) said this week that the FDA approved the company’s once-daily eye drop Rocklatan for the treatment of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension. The Durham, N.C.-based company’s product is a fixed-dose combination of latanoprost and netarsudil – the active ingredient in Aerie’s first drug, Rhopressa. Get the full story at our sister site, Drug Delivery Business News. The post Aerie wins FDA nod for second glaucoma drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 14, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat Aerie Pharmaceuticals Source Type: news

FDA OKs Rocklatan, a New Once-Daily Eye Drop for Glaucoma FDA OKs Rocklatan, a New Once-Daily Eye Drop for Glaucoma
The netarsudil and latanoprost ophthalmic solution (Rocklatan) reduces elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 13, 2019 Category: Drugs & Pharmacology Tags: Ophthalmology News Alert Source Type: news

FDA Approves Rocklatan (netarsudil and latanoprost ophthalmic solution) for the Reduction of Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension
DURHAM, N.C.--(BUSINESS WIRE)--Mar. 12, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 12, 2019 Category: Drugs & Pharmacology Source Type: news